kb 5492 has been researched along with geranylgeranylacetone in 2 studies
| Studies (kb 5492) | Trials (kb 5492) | Recent Studies (post-2010) (kb 5492) | Studies (geranylgeranylacetone) | Trials (geranylgeranylacetone) | Recent Studies (post-2010) (geranylgeranylacetone) |
|---|---|---|---|---|---|
| 8 | 0 | 0 | 317 | 25 | 109 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morimoto, Y; Oshima, S; Shimohara, K; Sukamoto, T | 1 |
| Hara, H; Morimoto, Y; Oshima, S; Shimohara, K; Sukamoto, T | 1 |
2 other study(ies) available for kb 5492 and geranylgeranylacetone
| Article | Year |
|---|---|
Effects of the new anti-ulcer agent KB-5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine.
Topics: Administration, Oral; Animals; Anti-Ulcer Agents; Cimetidine; Diterpenes; Gastric Acid; Gastric Mucosa; Hexosamines; Male; Piperazines; Rats; Rats, Inbred Strains; Stomach Ulcer | 1991 |
Effects of KB-5492, a new anti-ulcer agent with a selective affinity for the sigma-receptor, on aspirin-induced disruption of the rat gastric mucosal barrier.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Anti-Ulcer Agents; Aspirin; Diterpenes; Gastric Mucosa; Hydrogen; Male; Membrane Potentials; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sodium | 1994 |